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Abstract The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 brought back
memories of the occurrence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002. More than
1500 MERS-CoV cases were recorded in 42 months with a case fatality rate (CFR) of 40%. Meanwhile, 8000 cases
of SARS-CoV were confirmed in six months with a CFR of 10%. The clinical presentation of MERS-CoV ranges
from mild and non-specific presentation to progressive and severe pneumonia. No predictive signs or symptoms
exist to differentiate MERS-CoV from community-acquired pneumonia in hospitalized patients. An apparent
heterogeneity was observed in transmission. Most MERS-CoV cases were secondary to large outbreaks in
healthcare settings. These cases were secondary to community-acquired cases, which may also cause family
outbreaks. Travel-associated MERS infection remains low. However, the virus exhibited a clear tendency to cause
large outbreaks outside the Arabian Peninsula as exemplified by the outbreak in the Republic of Korea. In this
review, we summarize the current knowledge about MERS-CoV and highlight travel-related issues.
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Introduction
The emergence of Middle East respiratory syndrome
coronavirus (MERS-CoV) in 2012 brought back memories
of the occurrence of severe acute respiratory syndrome
coronavirus (SARS-CoV) in 2002 [1,2]. As of March 17,
2016, 1715 MERS-CoV cases were confirmed with a case
fatality rate (CFR) of approximately 40%, whereas 8000
SARS-CoV cases were recorded in six months with a 10%
CFR [1–3]. An upsurge in the number of cases was
observed in March–May 2014 because of the outbreak in
large healthcare facilities in Jeddah, Kingdom of Saudi
Arabia (KSA) [4,5]. More recently, a larger outbreak
occurred in Riyadh, KSA and in multiple hospitals in
South Korea [6–9].
Wolfe et al. [10] described the five stages of pathogen
evolution that lead to diseases confined to humans. In stage
1, the pathogen is confined to an animal host. Humans
become infected by animals only in stage 2. Stage 3 is
limited human-to-human transmission. In stage 4, long
outbreaks with numerous cycles of human-to-human
transmission occur. In stage 5, the pathogen exclusively
infects humans [10]. MERS-CoV has not yet reached stage
5. The interest and concern of the public and the health
community in emerging infectious diseases stem from the
ability of the emerging pathogens to cause pandemics with
high fatality rates and the associated economic effects on
affected countries. For example, SARS-CoV caused $30–
50 billions of economic losses in Mainland and Hong
Kong of China, Singapore, and Canada, and the pandemic
influenza H1N1 in 2009 resulted in $45–55 billion losses
worldwide [11]. In this review, we focus on the important
aspects of the recently emerged MERS-CoV, its effects on
humans, and the transmission patterns of the disease based
on available scientific data.
Timeline of MERS-CoV epidemic
The first reported MERS-CoV case from KSA was a 60-
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year-old male from Bisha [12,13]. The patient was
hospitalized with community-acquired pneumonia; the
disease rapidly progressed, resulting in acute renal failure,
respiratory failure, and death [13]. A summary of the major
events in the development of the MERS-CoV epidemic is
shown in Fig.1.
Contact and environmental investigations
Since the first case of MERS-CoV, a detailed investigation
was conducted to determine the environmental and animal
source of the virus. Extensive contact investigation was
carried out on the first case that originated from Bisha but
was eventually hospitalized in a private hospital in Jeddah
[12,14]. The contact investigation started in the patient’s
hometown of Bisha in southern KSA. The investigation
included his immediate household contacts (3 wives, 10
sons, 11 daughters, 12 grandchildren, and 1 house maid),
as well as the community and healthcare facility in Bisha,
which included 2 shepherds who took care of his five
camels and 14 healthcare workers (HCWs) (11 nurses and
three physicians) [14]. In total, 53 contacts in Bisha were
screened and all of them tested negative for MERS-CoV
by polymerase chain reaction (PCR) [14]. An extensive
investigation of the 48 out of 56 HCW who had significant
contact with the same patient during his 10-day stay in the
private hospital in Jeddah tested negative [15]. During the
October 2012 investigation on the source of the virus, a
team representing three agencies, namely, Saudi Ministry
of Health, Center for Infection and Immunity of Columbia
University, and EcoHealth Alliance, interviewed the
family of the index case-patient from Bisha. The team
also collected samples from bats within 12 km from his
home, as well as an abandoned date palm orchard, the area
within 1 km from his place of employment, a hardware
store that fronted his garden, and a date palm orchard.
Although none of his family members nor employees
recalled seeing bats, the investigating team observed the
roosting bats and guano in abandoned wells and ruins
within 12 km of his home and insectivorous bats at dusk in
the garden behind his store. A sample from a Taphozous
perforatus bat (Egyptian tomb bat) captured in Bisha
showed 100% identity to the human β-CoV 2c EMC/2012
cloned from the index case-patient [16]. The largest data
set on the contact investigation revealed that the percentage
of positive cases was 2.5%, 1.12%, 3.03%, and 2.09%
among hospital patients, HCW contacts, family and
contacts, and overall [17].
With the expansion of testing to identify the full disease
spectrum and the inclusion by the World Health Organiza-
tion (WHO) of the positive cases by serology in July 2014
[18], the CFR gradually decreased from 60% to 40% as
more asymptomatic and mildly symptomatic cases were
included [19]. A nationwide serosurvey for MERS-CoV
conducted in the KSA between December 2012 and
December 2013 suggested that around 45 000 infected
individuals were not aware of their infection, which
confirmed an extremely high incidence of asymptomatic to
mildly symptomatic disease [20].
Family clusters
A good example of a family cluster of MERS-CoV
infections was published in the New England Journal of
Medicine [21]. Once the second case in that cluster was
identified, an epidemiologic investigation identified the
index case who was the father of the second case who was
admitted earlier with congestive heart failure and commu-
nity-acquired pneumonia. Subsequently, the third and
fourth cases where recognized [21]. In that cluster, 28
persons lived in the same extended household, including
nine children ( < 14 years of age) [21]. Aside from the
Fig. 1 A summary of the major events in the timeline of MERS-CoV epidemic.
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four patients, no other family members had major
respiratory symptoms and none of the 124 HCWs who
managed the index case before the MERS-CoV diagnosis
exhibited symptoms [21]. A second family cluster was also
described by Omrani et al. [22]. Three patients lived in one
large house in urban Riyadh. None of the other family
contacts had positive PCR tests. Community outbreak was
also described [23]. The first patient infected his cousin,
and each of the patients infected their parents. Genome
analysis showed multiple introduction of the virus and
determined three distinct genotypes, which confirm very
low patient-to-patient transmission [23–26].
Healthcare-associated outbreaks
A number of healthcare-associated outbreaks were
reported previously [14,19,27,28]. A cluster of acute
respiratory illnesses was reported in the intensive care
unit (ICU) in Zarqa, Jordan in April 2012 [29]. Thirteen
HCW cases were detected (intensivists and ICU nurses)
with two mortalities. An initial investigation revealed no
etiology. After the announcement of the first case of
MERS-CoV in September 2012 in KSA, samples from
these patients were retested for MERS-CoVand confirmed
to be positive in two patients by PCR and eight contacts by
serology [29,30]. Thus, this case demonstrated MERS-
CoV as a healthcare outbreak. The second large outbreak
occurred in Al-Hasa, KSA in April 2013 [26]. A total of 23
confirmed cases and 11 probable cases were recorded. A
detailed transmission map was drawn based on the best
available epidemiological data linking these patients
epidemiologically [26]. Subsequent genotyping showed
multiple introduction of the virus leading to the outbreak
rather than a single introduction [25]. Four of the cases did
not match the transmission, which indicates that the
disease was not likely transmitted between the cases but
had a different genome, thus indicating multiple commu-
nity introductions [25]. The outbreak was controlled with
simple infection control measures in three weeks. MERS-
CoV was shown to have minor clades, and the most recent
common ancestor of MERS-CoV was introduced into
humans at the end of 2010 [31]. MERS-CoV is closely
related to Pipistrellus bat CoV HKU5 (Pi-BatCoV HKU5)
in bats from Hong Kong and these bats diverged from a
common ancestor several centuries ago [32].
In 2014, one of the largest healthcare-associated
outbreaks of MERS-CoV infection took place between
February 17 and April 26 in Jeddah, KSA [4]. A total of
128 MERS-CoV patients were treated in 14 hospitals [4,5].
The number of cases in each hospital varied from 2 to 45
cases [4,5]. In all the cases, 33% were primary cases and
60% (including 39 HCW) were healthcare-associated
infections [33]. The rapid increase in the cases was
attributed to more sensitive case detection, active case
determination, and contact tracing with changes in testing
algorithms [4]. A breakdown in infection control measures
was observed with no change in the virus [4]. A near full
genome sequence of the three viruses from the early phase
of the Jeddah outbreak showed a highly similar virus with
no genome insertions or deletions [4]. The genetic marker
influencing transmissibility was 100% identical to known
MERS-CoV genomes [4].
In 2015, the largest outbreak outside the Middle East
took place in South Korea [6]. The index case was a 68-
year-old male who visited Bahrain, KSA, United Arab
Emirates, and Qatar [6]. He developed symptoms on May
11, 2015 and visited multiple hospitals in South Korea [6].
He caused an outbreak involving five health care facilities
and 63 cases [7], with 34 cases in hospital B, 18 cases in
hospital D, 5 cases in hospital E, and three cases in hospital
F [7]. As of June 19, 2015 the outbreak in the Republic of
Korea involved 72 health care facilities, and six facilities
exhibited nosocomial transmission [8]. The total number
of cases as of July 21, 2015 was 186 cases with 36 deaths
[34,35].
Seasonality
Based on epidemiological data monitoring over the last
three years, the potential seasonality of MERS-CoV from
March to May and from September to November was
observed. In April and May 2014, the number of cases
increased [4]. One of the reasons for this increase in the
number of cases is the parallel surge in MERS-CoV tests in
Jeddah [4]. This increase is also facilitated by an intensified
intra-hospital and inter-hospital transmission of MERS-
CoV with no change in the virus genetic composition or
ability to cause disease [4,27]. Thus, seasonality is difficult
to establish because sporadic cases were documented with
amplifications mainly occurring during nosocomial out-
breaks.
Clinical presentation
Available data to date show that MERS-CoV behaves
differently in various conditions and in different popula-
tion of patients. Isolated sporadic cases, small family
clusters, as well as large healthcare-acquired infections and
clusters, were recorded. Most cases present with respira-
tory symptoms and about one-third had gastrointestinal
symptoms (Table 1) [26,36–40]. Early symptoms are mild
and non-specific, which last several days prior to
progressing to severe pneumonia. No predictive signs or
symptoms exist to differentiate MERS-CoV from commu-
nity-acquired pneumonia in hospitalized patients [38]. An
apparent heterogeneity in transmission was observed. The
severity of the disease is usually seen in primary or index
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cases, immune-compromised individuals, and people with
underlying comorbidities. Mild or asymptomatic disease
usually occurs in secondary cases and was initially thought
to infect the young and previously healthy individuals.
However, mortalities and severe cases were observed
among primary cases and young individuals [10]. How-
ever, person-to-person transmission as a definite route of
transmission is still unclear. The median incubation period
was 5.2 days (95% CI, 1.9 to 14.7), and the serial interval
was 7.6 days (95% CI, 2.5 to 23.1) [26]. CFR is directly
related to the number of comorbidities, the increasing
detection of asymptomatic to mildly symptomatic cases
over the last three years [39]. However, mortalities were
reported among healthy individuals. The median time to
hospitalization was 4 days, ICU admission was 5 days,
mechanical ventilation was 7 days, and death was 11.5
days [26,41].
Laboratory samples
MERS-CoV PCR was standardized, and it works extre-
mely well with lower respiratory samples in experienced
laboratories. Confirmatory testing in national or regional
reference laboratories with experience and load of samples
will avoid reporting false positive cases. On November 5,
2013, a Spanish case from Hajj was initially tested positive
for MERS-CoV but was eventually sent to an outside
reference laboratory for confirmatory testing; all tests were
negative [42]. If MERS-CoV infection is suspected and
initial testing is negative, repeat testing is recommended
and lower respiratory tract samples would yield higher
positivity [43]. In July 2014, a key change in MERS-CoV
case definition is the inclusion of a confirmed case based
on serology [44]. Serologic MERS-CoV confirmation
requires sero-conversion in two samples taken at least 14
days apart by a screening (ELISA, IFA) and a neutraliza-
tion assay [44].
Travel-related MERS-CoV
Since the emergence of MERS-CoVand till October 2015,
1715 cases were reported in different countries [45]. The
cases included 1403 cases in the Middle East, 15 cases in
Europe, 191 in Asia, and 7cases in other countries [45].
The WHO International Health Regulations (IHR) Emer-
gency Committee convened a MERS-CoV emergency
committee meeting on multiple occasions; after extensive
deliberations and reviews of available data, the diseases
Table 1 Summary of the number of cases of MERS-CoV with designated symptoms and signs from four different studies and the total percentage of
patients with any given symptom or sign
Assiri et al. [26] Saad et al. [36] Al-Tawfiq et al. [37] Arabi et al. [38] Assiri et al. [39] Shalhoub et al. [40]
Total 23 70 17 12 47 24
Male 17 46 11 8 36 14
Diabetes mellitus 17 ‒ 13 8 32 15
Cardiac disease 9 ‒ 11 7 13 0
Renal failure 12 ‒ ‒ 5 23 10
Hemodialysis ‒ ‒ 5 1 ‒ 6
Malignancy ‒ ‒ 1 1 1 0
Hypertension ‒ ‒ 6 6 16 18
Fever 20 43 10 8 46 19
Dyspnea 11 42 1 11 34 20
Chest pain ‒ ‒ 12 10 7 0
Cough 20 38 1 1 39 21
Hemoptysis ‒ 6 1 1 8 ‒
Sore throat ‒ ‒ 1 2 10 ‒
Headache ‒ 9 1 3 6 ‒
Myalgia ‒ 14 1 ‒ 15 ‒
Vomiting 4 21 1 ‒ 10 4
Diarrhea 5 21 1 2 12 3
Weakness ‒ 21 1 2 12 ‒
Abdominal pain ‒ 17 ‒ ‒ 8 2
Rhinorrhea ‒ ‒ 6 1 2 ‒
Lymphopenia ‒ 36 ‒ 9 16 ‒
Thrombocytopenia 4 ‒ ‒ 2 17 ‒
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did not fulfill the IHR requirements to be defined as a
public health emergency of international concern (PHEIC)
and mainly sustained human-to-human transmission
[46,47] (Fig.2).
Using a mathematical model, the risk of MERS-CoV
was estimated to be one to seven cases per Hajj and three to
ten Umrah pilgrims per year [48]. In another model, 6.2
pilgrims were estimated to develop MERS-CoV symptoms
during the Hajj, and 4.0 foreign pilgrims will be infected
but return home before developing symptoms [49]. Travel-
related MERS-CoVoccurred infrequently among pilgrims
performing the Umrah [50]. However, millions of pilgrims
who performed the annual Hajj did not exhibit MERS-
CoV symptoms [51]. A cross sectional study of 839
African Hajj pilgrims returning to Ghana, West Africa in
2013 showed that none of the pilgrims was positive for
MERS-CoV [52]. A cohort of French pilgrims exhibited
no MERS-CoV infection [53]. No MERS-CoV was
detected by PCR among 5235 adult pilgrims from 22
countries [54]. Although the risk of travel-associated
MERS-CoV remains low, the potential for healthcare-
associated infections in relation with an imported MERS-
CoV is a real concern. This event took place in the
Republic of Korea [6–9]. Thus, all HCWs should be
vigilant to the importation of MERS from returning
travelers and healthcare organizations should implement
a strategy to screen, isolate, and diagnose these patients.
Seroprevalence of MERS-CoV
Serologic testing allowed the detection of eight of the 124
contacts in the Jordan cluster [30]. The positive results
were confirmed in six of nine outbreak members, one in 26
household contacts, and one in 89 HCWs [30]. Interest-
ingly, one HCW who tested positive did not recall having
respiratory symptoms at the time of the outbreak [30]. A
few published serology studies did not present any
background on MERS-CoV. In one study, eight out of
356 abattoir workers and blood donors had weak positive
tests by IFA, and none of these individuals tested positive
by NT in Jeddah and Makkah in 2012 [55]. In a second
study, none of 268 children with respiratory tract disease
and blood donors showed neutralizing antibodies in
Dammam, KSA in 2010–2012 [55].
An initial study of 268 samples that were tested for
MERS-CoV antibodies in the Eastern Saudi Arabia
revealed no positive samples [55]. A serologic evaluation
of 280 household contacts of 26 index patients showed 12
probable cases of secondary transmission (4%; 95%
confidence interval, two to seven) [56]. A large-scale
study of more than 10 000 samples demonstrated that the
overall seroprevalence in KSAwas 0.15% and detected an
increase of 17- and 26-fold of antibody detection rate
among camel shepherds and abattoir workers compared to
that in the general population [20].
MERS-CoV genome sequences
The full genome sequences from MERS patients with
known dates and locations can help answer these
questions: How fast does the virus change? When did the
virus begin circulating in its current form? Is the virus
adapting to humans? Can the geographical patterns help
locate an animal source? What are the transmission
patterns? A previous study showed that sequence success
is as function of viral load, which is inversely proportional
to the threshold cycle value (Ct) in real-time PCR assays
[25]. Ct values below 33 are associated with good
Fig. 2 Timeline of WHO Emergency Committee (EC) meeting to discuss the IHRMERS-COV situation in relation to major events in the time of the
disease.
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sequencing success rates. Thus, Ct values are sufficient
predictors of the success that is independent on sample
type or source [24,25].
Infection control
MERS-CoV was found to be stable in the environment.
The virus can survive on plastic and steel for up to 48 h at
lower temperatures and humidity; once temperature and
humidity increase, the virus becomes less viable [57]. The
virus is viable at 20 °C and 40% humidity for 48 hours, at
30 °C and 30% humidity for 24 hours and at 30 °C and
80% humidity for 8 hours only [57]. In another study,
increasing the temperature from 25 °C to 65 °C adversely
affects viral infectivity [58]. The WHO advocates contact
and droplet precautions with airborne isolation in hospital
settings when dealing with an aerosol-generating proce-
dure [56]; the United States Centers for Disease Control
and Prevention (CDC) and the European Centre for
Disease Prevention and Control (ECDC) call for airborne
infection isolation precautions [59–61].
Multiple hospital outbreaks of MERS-CoV infection in
KSA were controlled effectively using infection control
precautions recommended by the WHO and the Saudi
Ministry of Health [4,5,26,36].
Therapeutic options
There are no proven therapeutic agents for the treatment of
MERS-CoV patients. Existing antiviral agents can be
repurposed against MERS-CoV [62,63]. Interferon and
ribavirin were suggested to be possible therapeutic options
based on the SARS data [63]. These two agents were used
to treat five patients with MERS-CoV infection [64]. The
median time to therapy was 19 days, and no improvement
was observed [64]. Ribavirin and interferon were used in
20 patients with MERS-CoV at a median of three days
[65]. The 14-day survival was 70% (14 of 20 patients) in
the treatment group vs. 29% (7 of 24 of patients) in a
historical group (P = 0.004) with no survival improvement
at 28 days (30% vs. 17%; P = 0.054) [63]. In an
observational study, interferon-α2a with ribavirin and
interferon-β1a with ribavirin showed similar results in
treating MERS-CoV [40].
The potential repurposed drugs for MERS therapy
include ribavirin with or without interferon, HIV protease
inhibitors (lopinavir and nelfinavir), cyclophilin inhibitors
(cyclosporin and alisporivir), chloroquine, mycophenolic
acid, and nitazoxanide [66]. The use of interferon-α2b and
ribavirin decreased viral replication in the rhesus macaques
model within 8 h of MERS-CoV infection [67]. In vitro,
ribavirin inhibits MERS-CoV; however, the required doses
are extremely high to obtain in vivo [68,69].
In vitro, nelfinavir and lopinavir achieved inhibitory
concentrations against MERS-CoV [70]. In a primate
model, the mortality rate at 36 h post-inoculation was 67%
in untreated versus 0%–33% in the lopinavir- or ritonavir-
treated and interferon-β1b-treated animals [71]; the
combination was used in another case [72].
Future directions
To understand the MERS-CoV disease further, resolving
the issues related to the specific host and the specific
transmission mode and determining the factors that
increase transmission within healthcare environments are
crucial. The viral kinetics of MERS-CoV within different
body compartments is another aspect that needs further
examination. The optimal therapeutic options and strate-
gies to predict the occurrence and severity of the disease
require further analysis.
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